ANNOUNCEMENT Synthetic mRNAs; Their Analogue Caps and Contrib | Peter A. McCullough, MD, MPH™

ANNOUNCEMENT

Synthetic mRNAs; Their Analogue Caps and Contribution to Disease
Citation: Kyriakopoulos, A.M.; McCullough, P.A. Synthetic mRNAs; Their Analogue
Caps and Contribution to Disease. Diseases 2021, 9, 57. https://doi.org/10.3390/

diseases9030057

Cellular and hence organism (mammalian and Human), homeostasis is finely
balanced. Evolution has devised specific cap structures of mRNAs that provide and
maintain the first and most important line of innate defense against viral and other
microbial pathogens. Proper mRNA cap structure regulation also protects the cell and
hence the organism from auto-immunity, cancer, developmental and other immune
malfunctioning. The synthetic mRNAs used for vaccination, primarily against cancer
and genetic disorder therapy, and nowadays vastly against infectious diseases have
chemically (in vitro) synthesized analogue caps with the scope to offer stability and
increase efficiency and potency of translation of their encoded sequences. This
potentiating ability of analogue caps of synthetic mRNAs can lead to disease. The
central molecule, the elF4E which is regarded as a potent oncogene with the ability to govern cell
cycle progression and proliferation at a post-transcriptional level, and may cause disease progression due to lasting binding dependence to cap structures as those
incorporated in the synthetic mRNA macromolecules. mTOR and elF4E cellular
sensitivities, increase vulnerability to further microbial (including viral) infections,
autoimmunity and cancer progression. This thorough review describes the molecular
pathways and links to the pathology progression of severe diseases as an outcome of
analogue caps in synthetic mRNAs.